Baseline cost-effectiveness analysis and probabilistic sensitivity analysis
| Strategy . | Costs (US$) . | Incremental osts (US$) . | Effectiveness (QALY) . | Incremental effectiveness (QALY) . | ICER ($/QALY) . | ICER 95% CI ($/QALY) . |
|---|---|---|---|---|---|---|
| SOC | 155 806 | – | 3.16 | – | – | – |
| SOC + caplacizumab | 566 202 | 410 397 | 3.44 | 0.28 | 1 457 042 | 1 247 932-1 721 616 |
| Strategy . | Costs (US$) . | Incremental osts (US$) . | Effectiveness (QALY) . | Incremental effectiveness (QALY) . | ICER ($/QALY) . | ICER 95% CI ($/QALY) . |
|---|---|---|---|---|---|---|
| SOC | 155 806 | – | 3.16 | – | – | – |
| SOC + caplacizumab | 566 202 | 410 397 | 3.44 | 0.28 | 1 457 042 | 1 247 932-1 721 616 |
CI, confidence interval; costs, total costs of the standard of care and SOC + caplacizumab arms; effectiveness, added benefit in QALY of SOC and SOC + caplacizumab, using the assumptions described in the manuscript for utilities of the well and disease states; incremental costs, added cost of SOC + caplacizumab compared with SOC; incremental effectiveness, difference in effectiveness between SOC vs SOC + caplacizumab. The ICER is calculated by dividing incremental cost by incremental effectiveness.